Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gadobutrol-enhanced CMRI for Detection of CAD
NCT01890434Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2013
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of gadobutrol in coronary artery disease (CAD), sponsored by Bayer. Primary endpoints: Sensitivity of Gadobutrol-enhanced CMRI for Detection of Significant CAD, Specificity of Gadobutrol-enhanced CMRI for Exclusion of Significant CAD and 1 more. Started Aug 2013; status: completed.
02
Drugs
gadobutrol
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01890434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01890434.